CU2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueINTERCEPT’s single-use consumables create a high-frequency, repeat-purchase revenue stream tied to procedure volumes. That recurring consumable model supports predictable top-line durability, strong customer switching costs, and long-term revenue visibility as installed base and procedure volumes scale.
Sustained Revenue Growth With Raised GuidanceAcceleration in product revenue and an upward guide signal durable commercial traction across platelets, IFC and EMEA. Consistent double-digit growth plus management's raised guidance indicates expanding adoption and provides a multi-quarter runway for operating leverage and investment in commercialization.
Improving Leverage And LiquidityMeaningful debt reduction and stronger equity improve financial flexibility and reduce refinancing pressure. A cash balance (~$80M) plus amended credit facilities provide runway to fund regulatory launches and working-capital needs, lowering short-to-medium-term solvency risk while commercialization scales.
Bears Say
Persistent GAAP LossesDespite improving adjusted metrics, GAAP losses and negative TTM EBITDA constrain the company’s ability to self-fund growth and deliver shareholder returns. Continued unprofitability leaves Cerus exposed to revenue shortfalls and increases dependency on external financing for larger commercial or regulatory investments.
Gross Margin CompressionMaterial margin decline driven by inflationary shipping/fuel costs, tariffs and FX reduces operating leverage and long-term cash conversion. If margins remain in the low‑fifties, it will be harder to translate revenue growth into sustainable GAAP profitability and free cash flow.
Regulatory And Rollout Timing RiskKey RED program regulatory timing and a lumpy early-stage IFC rollout create single-event risk to material revenue milestones. Combined with working-capital-driven inventory builds, timing slips could delay revenue recognition and pressure near-term cash flow and investment plans.
Cerus News
CU2 FAQ
What was Cerus Corp’s price range in the past 12 months?
Currently, no data Available
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is CHF478.04M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Jul 30, 2026 which is in 3 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Apr 30, 2026. The company reported -CHF0.008 earnings per share for the quarter, beating the consensus estimate of -CHF0.033 by CHF0.024.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 200,368,970 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -CHF0.008 in its last earnings report, beating expectations of -CHF0.033. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CH:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF3.66 (― Upside)
CHF3.66 (― Upside)
Blogger Sentiment
Bullish
CH:CU2 Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $53.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Cerus Corp
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and operational positives: strong Q1 top-line performance (24% product revenue growth), raised full-year guidance, robust IFC/platelet momentum, continued positive adjusted EBITDA, disciplined operating expense control, and advancing regulatory/product milestones (illuminator PMA submission and RBC trial readout). Offsetting these positives are persistent margin headwinds (gross margin down to 52%), macro pressures (inflation, tariffs, FX), regional logistical risks (Middle East), working capital-driven cash use, and timing uncertainty around the red blood cell CE Mark and the lumpy nature of IFC rollout. On balance, the highlights—notably recurring revenue growth, improved profitability trends, and strengthened guidance—outweigh the lowlights, though management cautions about margin and timing risks.View all CH:CU2 earnings summariesCU2 Stock 12 Month Forecast
Average Price Target
―Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―